BioSpace News Archive

Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that it has appointed Howard M. Lazarus, M.D., to the newly created position of Chief Medical Officer.

CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the recent publication entitled, “Intraoperative hemoadsorption in patients with native mitral valve endocarditis,” in the journal, The Annals of Thoracic Surgery.

$10 Million Gift from the Pincus Family Foundation Advances Children’s Health Worldwide

EmblemHealth, one of the nation’s largest non-profit health insurers, announced it was named the winner of two Stevie® Awards in the 14th annual Awards for Sales & Customer Service.

Marker Therapeutics, Inc. announced that the Company has entered into a Common Stock Purchase Agreement of up to $30 million with Aspire Capital Fund, LLC, a Chicago-based institutional investor and long-term Marker shareholder.

Theravance Biopharma, Inc. (NASDAQ: TBPH)today announced the closing of a private placement of $400 million of non-recourse Triple II 9.5% fixed rate term notes.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA” (TSX VENTURE: IPA) (OTC QB: IPATF), through its subsidiary, Talem Therapeutics (talemtherapeutics.com), and the New York-based company EVQLV, Inc. (evqlv.com), announces a new collaboration aimed at accelerating the global effort to develop lead therapeutic and vaccine candidates against the SARS-CoV-2 virus.

Series B Proceeds will Advance XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA4) into the Clinic while Expanding Xilio’s Tumor-Selective Cytokine Pipeline

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its fourth quarter and full year 2019 financial results on Monday, March 9, 2020.

Quantum-Si, a Connecticut-based start-up, today introduced the world’s first next-generation protein sequencing platform at Cowen Healthcare 2020